Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

Nicole DeFeudis

Editor

Lea Hachigian, a principal at the Longwood Fund, recalls working with Harvard professor Stephen Elledge three years ago on the launch of TCR-focused TScan Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

Nicole DeFeudis

Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Stephen Elledge's Har­vard lab takes $17M to birth Im­muneID, a high-through­put an­ti­body start­up

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup